Certara Completes Acquisition of Chemaxon
Certara, Inc. (NASDAQ: CERT), a prominent player in model-informed drug development, has successfully finalized its acquisition of Chemaxon. This strategic move positions Certara to expand its technological capabilities significantly.
Enhancing Drug Development
The integration of Chemaxon’s cutting-edge scientific informatics software will greatly benefit life sciences companies. Chemaxon is renowned for its innovative products that facilitate in-silico research, crucial for modern pharmacological studies.
Transforming Research through Technology
Certara's advanced modeling and biosimulation tools are designed to predict the pharmacokinetic and pharmacodynamic profiles of compounds. By merging these capabilities with Chemaxon's software, Certara aims to provide life sciences companies with powerful insights that enhance their research productivity.
CEO Insights on the Acquisition
William Feehery, the CEO of Certara, expressed enthusiasm over the acquisition, stating, "The combination allows scientists to gain more precise insights throughout the drug development process." With this acquisition, the two entities can offer improved solutions tailored to the evolving needs of drug discovery.
Focus Areas Post-Acquisition
Following the acquisition, Certara is prioritizing the integration of Chemaxon's precision chemistry structures and predictors into its product lineup. Enhancements to the D360 scientific applications and Simcyp™ PBPK Simulator are anticipated to ensure better prediction accuracy for drug development.
Future Collaborations and Developments
Long-term aspirations include leveraging Certara.AI's specialized capabilities to refine the drug discovery process further. By integrating this artificial intelligence expertise with Chemaxon’s offerings, including Design Hub and JChem Engines, Certara will be at the forefront of innovation in life sciences.
The Path Ahead for Chemaxon
Looking ahead, Chemaxon is projected to generate software revenues exceeding $20 million. Certara plans to update its revenue forecasts to reflect Chemaxon’s contributions in the upcoming quarterly earnings report.
Importance of Precision Medicine
The CEO of Chemaxon, Richard Jones, emphasized the importance of accurate scientific predictions in drug development, especially as the focus shifts towards precision medicine therapies. "Our teams are excited to make a substantial impact on drug discovery practices," he proclaimed.
About Certara
Certara is committed to advancing medicine development through biosimulation software and technology. They support over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory bodies, across a vast international landscape.
About Chemaxon
Chemaxon specializes in cheminformatics, offering platforms and solutions that enhance the management of chemical entities across diverse research fields, including biotechnology and agriculture.
Contact Information for Certara
For more inquiries, reach out to Sheila Rocchio at sheila.rocchio@certara.com.
Media Inquiries
For media-related questions, contact Alyssa Horowitz at certara@pancomm.com.
Frequently Asked Questions
What does Certara do?
Certara specializes in model-informed drug development and uses biosimulation to enhance drug discovery processes.
What is the significance of acquiring Chemaxon?
The acquisition enhances Certara’s ability to offer integrated scientific informatics solutions for the life sciences industry.
How will this acquisition impact drug development?
It will improve productivity and the success rates of scientific innovation in drug discovery.
What are Certara's next steps post-acquisition?
Certara plans to integrate Chemaxon's tools and solutions into its existing product offerings.
How can I contact Certara for more information?
You can reach Certara representatives via email at sheila.rocchio@certara.com for any inquiries.
